Improving treatment recommendations for children with retinoblastoma in Africa
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
French Africa Pediatric Oncology Group · NCT04425434
This study is trying to see if better treatment recommendations and early diagnosis can help improve survival rates for children with retinoblastoma in Africa.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | French Africa Pediatric Oncology Group (other) |
| Locations | 7 sites (Ouagadougou and 6 other locations) |
| Trial ID | NCT04425434 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the outcomes for children diagnosed with retinoblastoma, particularly in low-income countries in Africa. By focusing on early diagnosis and the implementation of therapeutic recommendations, the study seeks to demonstrate that timely intervention can significantly improve survival rates. Data will be collected on the stage of the disease, treatment methods, and patient outcomes to analyze the effectiveness of these recommendations.
Who should consider this trial
Good fit: Ideal candidates include children with unilateral or bilateral intraocular retinoblastoma or unilateral extraocular intraorbital retinoblastoma.
Not a fit: Patients with advanced disease stages, such as externalized tumor masses or significant intracranial extension, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for children with retinoblastoma in low-income regions.
How similar studies have performed: While there have been successful studies in high-income countries, this approach is novel in the context of low-income countries and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Unilateral intraocular Retinoblastoma (RB) * Unilateral extraocular intraorbital (RB) * Bilateral intraocular (RB) * bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side. Exclusion Criteria: * Externalized tumor mass * massive extension to optic nerve up to optical channeltumor * intracranial extension leptomeninges * cerebral parenchyma * extension to regional lymph nodes and/or remote metastases. * cerebrospinal fluid involvement. * Trilateral RB * Incapacity to followed the whole treatement.
Where this trial is running
Ouagadougou and 6 other locations
- Hopital Yalgado Ouedraogo — Ouagadougou, Burkina Faso (RECRUITING)
- CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (RECRUITING)
- CUK (Cliniques Universitaires de Kinshasa) — Kinshasa, Kinshasa City, Democratic Republic of the Congo (RECRUITING)
- Cliniques Universitaires de Lubumbashi (CUL) — Lubumbashi, Democratic Republic of the Congo (RECRUITING)
- HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona — Antananarivo, Ampefiloha, Madagascar (RECRUITING)
- CHU Gabriel Touré (HGT) — Bamako, Mali (RECRUITING)
- Hôpital Aristide Le Dantec, — Dakar, Senegal (RECRUITING)
Study contacts
- Principal investigator: FOUSSEYNI Mr TRAORE, Dr; — AMCC AND GFAOP
- Study coordinator: KARIM Mr ASSANI, Dr.
- Email: drassanik@gmail.com
- Phone: 00243971359726
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Retinoblastoma